

# Susan M Ott

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9173937/susan-m-ott-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46  
papers

10,245  
citations

19  
h-index

49  
g-index

49  
ext. papers

11,041  
ext. citations

7.5  
avg, IF

5.56  
L-index

#	Paper	IF	Citations
46	Not etched in bone: the role of osteoclast proton-sensing receptors. <i>Kidney International</i> , <b>2021</b> , 99, 542-545	9.9	1
45	Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. <i>Kidney International</i> , <b>2021</b> , 100, 502-505	9.9	1
44	Osteoporosis associated with chronic kidney disease <b>2021</b> , 1325-1380		0
43	Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2025190	10.4	4
42	Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. <i>BMC Musculoskeletal Disorders</i> , <b>2020</b> , 21, 801	2.8	1
41	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1784-1802	4.7	5
40	Determinants of Oral Bisphosphonate Use Beyond 5 Years. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2020</b> , 26, 197-202	1.9	1
39	Renal Osteodystrophy and Bone Biopsy. <i>Nephrology Self-assessment Program: NephSAP</i> , <b>2020</b> , 19, 215-225		
38	Structural and Metabolic Assessment of Bone. <i>Handbook of Experimental Pharmacology</i> , <b>2020</b> , 262, 369-396		
37	Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2019</b> , 25, 719-723	1.9	3
36	Renal insufficiency and bone loss. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 394-399	5.3	0
35	Bones and the sex hormones. <i>Kidney International</i> , <b>2018</b> , 94, 239-242	9.9	6
34	Renal Osteodystrophy-Time for Common Nomenclature. <i>Current Osteoporosis Reports</i> , <b>2017</b> , 15, 187-193	5.4	10
33	Bone strength: more than just bone density. <i>Kidney International</i> , <b>2016</b> , 89, 16-9	9.9	16
32	Role of proton receptor OGR1 in bone response to metabolic acidosis?. <i>Kidney International</i> , <b>2016</b> , 89, 529-31	9.9	8
31	Bone cells, sclerostin, and FGF23: what's bred in the bone will come out in the flesh. <i>Kidney International</i> , <b>2015</b> , 87, 499-501	9.9	9
30	A comparison of self-reported oral contraceptive use and automated pharmacy data in perimenopausal and early postmenopausal women. <i>Annals of Epidemiology</i> , <b>2015</b> , 25, 55-9	6.4	4

29	Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease. <i>Seminars in Dialysis</i> , <b>2015</b> , 28, 363-9	2.5	13
28	Ethnic differences in bone and mineral metabolism in healthy people and patients with CKD. <i>Kidney International</i> , <b>2014</b> , 85, 1283-9	9.9	20
27	Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 2-17	6.3	1588
26	Therapy for patients with CKD and low bone mineral density. <i>Nature Reviews Nephrology</i> , <b>2013</b> , 9, 681-92	4.9	27
25	Debating the duration of bisphosphonate therapy. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , <b>2013</b> , 26, 64-5	0.8	1
24	Osteoporosis Associated with Chronic Kidney Disease <b>2013</b> , 1387-1424		1
23	Incidence of atypical nontraumatic diaphyseal fractures of the femur. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 2544-50	6.3	290
22	Bone disease in CKD. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2012</b> , 21, 376-81	3.5	10
21	Bisphosphonate safety and efficacy in chronic kidney disease. <i>Kidney International</i> , <b>2012</b> , 82, 833-5	9.9	22
20	What is the optimal duration of bisphosphonate therapy?. <i>Cleveland Clinic Journal of Medicine</i> , <b>2011</b> , 78, 619-30	2.8	42
19	Navel jewelry artifacts and intravertebral variation in spine bone densitometry in adolescents and young women. <i>Journal of Clinical Densitometry</i> , <b>2009</b> , 12, 84-8	3.5	11
18	Cystatin-C, renal function, and incidence of hip fracture in postmenopausal women. <i>Journal of the American Geriatrics Society</i> , <b>2008</b> , 56, 1434-41	5.6	61
17	Histomorphometric measurements of bone turnover, mineralization, and volume. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2008</b> , 3 Suppl 3, S151-6	6.9	47
16	What Are the Most Common Errors in the Management of Renal Osteodystrophy?. <i>Seminars in Dialysis</i> , <b>2007</b> , 2, 145-146	2.5	2
15	Does Estrogen Play a Role in Renal Osteodystrophy?. <i>Seminars in Dialysis</i> , <b>2007</b> , 8, 4-11	2.5	1
14	Mineral changes in osteoporosis: a review. <i>Clinical Orthopaedics and Related Research</i> , <b>2006</b> , 443, 28-38	2.2	111
13	Letter re: Alendronate in Anorexia Nervosa. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 5508-5508	5.6	2
12	Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , <b>2002</b> , 17, 341-8	6.3	87

11	Histomorphometric Analysis of Bone Remodeling <b>2002</b> , 303-319		20
10	Bone structure in patients with low bone mineral density with or without vertebral fractures. <i>Journal of Bone and Mineral Research</i> , <b>2000</b> , 15, 1368-75	6.3	81
9	Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. <i>Journal of Bone and Mineral Research</i> , <b>1998</b> , 13, 415-21	6.3	82
8	Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. <i>Lancet, The</i> , <b>1996</b> , 348, 1535-41	40	3001
7	Bone formation periods studied with triple tetracycline labels in women with postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>1993</b> , 8, 443-50	6.3	9
6	Clinical effects of bisphosphonates in involutional osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>1993</b> , 8 Suppl 2, S597-606	6.3	16
5	When bone mass fails to predict bone failure. <i>Calcified Tissue International</i> , <b>1993</b> , 53 Suppl 1, S7-13	3.9	75
4	Methods of determining bone mass. <i>Journal of Bone and Mineral Research</i> , <b>1991</b> , 6 Suppl 2, S71-6; discussion S83-4	6.3	15
3	D-lactate and metabolic bone disease in patients receiving long-term parenteral nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , <b>1989</b> , 13, 132-5	4.2	21
2	Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. <i>Journal of Bone and Mineral Research</i> , <b>1987</b> , 2, 595-610	6.3	4132
1	The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. <i>New England Journal of Medicine</i> , <b>1982</b> , 307, 709-13	59.2	314